TrueVue an innovative monitoring system to improve patient outcomes, reduce mortality and reduce healthcare costs

TrueVue 是一种创新的监测系统，可改善患者治疗结果、降低死亡率并降低医疗成本

• 批准号: 35023
• 金额: $ 44.59万
• 依托单位: DELTEX MEDICAL LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=35023
• 关键词: TrueVue; innovative; monitoring; system; improve

Deltex Medical has been awarded an Innovate UK Smart Award to develop TrueVue - a disruptive technology for the diagnosis and management of the haemodynamics of surgical and critical care patients. It is designed for all patients from new-born to adult, anaesthetised or awake, across all hospital settings. Medicine today faces increasingly complex cases as the population ages. Protecting patients from haemodynamic errors through improved monitoring would save thousands of lives, improve outcomes and reduce costs. Diagnostic haemodynamic equipment needs to display the interaction of blood flow and pressure if it is to be truly effective.Haemodynamic instability and low blood pressure are frequent, with consequences such as myocardial infarctions, stroke and kidney injury. Complications have serious clinical and financial consequences; unplanned intensive care admissions; longer hospital stay; increased readmissions; increased 30-day mortality; and shorter patient lifespan after discharge.Monitors dependent on blood pressure measurement alone are failing to meet this need for all patients across all hospital settings. The novel TrueVue Velocity Pressure Loops system is the first monitor to display both aortic blood flow and aortic blood pressure simultaneously throughout the heartbeat. TrueVue will be a significant contribution to patient safety for surgical and critical care patients.TrueVue will operate by use of Doppler ultrasound and other non-invasive methods to measure blood flow velocity and combine this with standard measures of arterial blood pressure. The system can currently be used in all major surgical procedures and intensive care units; and with developments in non-invasive methods already foreseen by Deltex, could be applied across all surgical and after care procedures.The UK is a global clinical leader in haemodynamics and Enhanced Recovery Programmes. TrueVue is based on sound haemodynamic practices and is both a significant patient safety advance and a global business opportunity for the UK. TrueVue will address a market need in the UK alone of nearly 600,000 surgical patients, 90,000 intensive care admissions and a global market of nearly 40million in major/high-risk surgery and ICU. With expansion into all categories of surgery through non-invasive methods the technology has a potential market of 278million procedures annually.Deltex Medical expects to increase its market share, and revenues 5-fold to £35m in the first 6 years of sales.

Deltex Medical 因开发 TrueVue 而荣获创新英国智能奖，这是一种用于诊断和管理外科和重症监护患者血流动力学的颠覆性技术。它专为所有医院环境中的所有患者（从新生儿到成人、麻醉或清醒状态）而设计。随着人口老龄化，今天的医学面临着越来越复杂的情况。通过改进监测来保护患者免受血流动力学错误的影响将挽救数千人的生命，改善结果并降低成本。血流动力学诊断设备要想真正有效，就需要显示血流和压力的相互作用。血流动力学不稳定和低血压经常发生，导致心肌梗塞、中风和肾损伤等后果。并发症会造成严重的临床和经济后果；计划外重症监护入院；住院时间较长；增加再入院人数； 30 天死亡率增加；出院后患者寿命较短。仅依靠血压测量的监护仪无法满足所有医院环境中所有患者的这一需求。新颖的 TrueVue VelocityPressure Loops 系统是首款在整个心跳过程中同时显示主动脉血流量和主动脉血压的监视器。 TrueVue 将为手术和重症监护患者的患者安全做出重大贡献。TrueVue 将使用多普勒超声和其他非侵入性方法来测量血流速度，并将其与动脉血压的标准测量相结合。该系统目前可用于所有主要外科手术和重症监护病房；随着 Deltex 已经预见到的非侵入性方法的发展，可以应用于所有手术和术后护理程序。英国是血液动力学和加速康复计划的全球临床领导者。 TrueVue 基于良好的血液动力学实践，对英国来说既是患者安全的重大进步，也是全球商机。 TrueVue 将满足仅英国近 600,000 名手术患者、90,000 名重症监护患者的市场需求以及近 4000 万大型/高风险手术和 ICU 患者的全球市场需求。随着通过非侵入性方法扩展到所有类别的手术，该技术每年拥有 2.78 亿例手术的潜在市场。Deltex Medical 预计将增加其市场份额，并在销售的前 6 年收入增加 5 倍，达到 3500 万英镑。